drugset / Trial / NCT06827457

A Study of Safety, Tolerability, PK, and PD of Subcutaneous GenSci120 in Healthy Adults.

NCT06827457

Phase 1 Completed 58 enrolled Changchun GeneScience Pharmaceutical Co., Ltd.
RandomizedParallel-groupDouble-blindOther

Summary

This study is designed to evaluate the safety, tolerability, PK and PD of GenSci120 in a randomized, double-blind, placebo-controlled trial involving healthy adult participants.

Timeline

Start
2025-02-20
Primary completion
2025-11-27
Completion
2025-12-16

Drugs

EvaluationDrugModalityDoseRoute
Subject GenSci120 Unknown Subcutaneous

Indications